Kei Yaginuma, Kazuhiro Takahashi, Seiji Hoshi, Taiki Joho, Saki Shimoyama, Naoko Hasegawa, Koki Hasegawa, Songji Zhao, Naoyuki Ukon, Syunta Makabe, et al. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. 2024
Muchtaridi Muchtaridi, Wiwit Nurhidayah, Taufik Fakih, Kento Kannaka, Hiroyuki Suzuki, Toto Subroto, Tomoya Uehara. Investigation of a Radio-Iodinated Alpha-Mangostin for Targeting Estrogen Receptor Alpha (ERα) in Breast Cancer: In Silico Design, Synthesis, and Biological Evaluation. Drug Design, Development and Therapy. 2024
Hiroyuki Suzuki, Kento Kannaka, Mizuki Hirayama, Tomoki Yamashita, Yuta Kaizuka, Ryota Kobayashi, Takahiro Yasuda, Kazuhiro Takahashi, Tomoya Uehara. In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure. EJNMMI Radiopharmacy and Chemistry. 2024
Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Development of a neopentyl 211At-labeled activated ester providing in vivo stable 211At-labeled antibodies for targeted alpha therapy. ChemMedChem. 2024
Hiroyuki Suzuki, Yuta Kaizuka, Maho Tatsuta, Hiroshi Tanaka, Nana Washiya, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Tadashi Watabe, Takahiro Teramoto, et al. Neopentyl glycol as a scaffold to provide radiohalogenated theranostic pairs of high in vivo stability. RIKEN Accelerator Progress Report 2021. 2021. 55. 137
Tomoya Uehara, Shota Kise, Hiroyuki Suzuki, Yasushi Arano. Development of Cu-64 labeling agent for low molecular weight peptides to reduce renal radioactivity level. Journal of Nuclear Medicine. 2020. 61. supplement 1. 1080
Development of in vivo stable 211At-labeled agents for effective targeted alpha therapy of cancers
(ナント大学セミナー 2024)
A novel approach to produce astatine-211-labeled agents for effective and safe targeted alpha therapy.
(The 4th CRI-CGI-Chiba symposium in Chemistry and Biomedical Sciences 2024)
Reduction of renal radioactivity levels of 111In-labeled antibody fragments.
(The 3rd CRI-CGI-Chiba Symposium in Chemistry 2023)